Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab + Chemotherapy +/- Venetoclax in Infants With Newly Diagnosed ALL
NCT06317662Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of venetoclax, blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Started Jun 2025; status: recruiting.
02
Drugs
venetoclaxblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06317662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06317662.